Negotiations for the sixth FDA Device User Fee Agreement (MDUFA VI) have commenced, revealing notable discrepancies between regulatory agency expectations and industry demands. Proposed fee increases are set to outpace inflation significantly, with projected workload reductions expected for certain application types. Stakeholders express concern over rising costs amidst shifting regulatory landscapes.